PL2610256T3 - Pochodne pirymidyny jako inhibitory kinaz białkowych - Google Patents

Pochodne pirymidyny jako inhibitory kinaz białkowych

Info

Publication number
PL2610256T3
PL2610256T3 PL13156251.4T PL13156251T PL2610256T3 PL 2610256 T3 PL2610256 T3 PL 2610256T3 PL 13156251 T PL13156251 T PL 13156251T PL 2610256 T3 PL2610256 T3 PL 2610256T3
Authority
PL
Poland
Prior art keywords
protein kinase
kinase inhibitors
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
PL13156251.4T
Other languages
English (en)
Polish (pl)
Inventor
Jonathan James Hollick
Start Donald Jones
Claire June Flynn
Michael George Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0719038A external-priority patent/GB0719038D0/en
Priority claimed from GB0806844A external-priority patent/GB0806844D0/en
Application filed filed Critical
Publication of PL2610256T3 publication Critical patent/PL2610256T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13156251.4T 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych PL2610256T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0719038A GB0719038D0 (en) 2007-09-28 2007-09-28 Compound
GB0806844A GB0806844D0 (en) 2008-04-15 2008-04-15 Compound

Publications (1)

Publication Number Publication Date
PL2610256T3 true PL2610256T3 (pl) 2016-11-30

Family

ID=40199600

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13156251.4T PL2610256T3 (pl) 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych
PL08806455T PL2205603T3 (pl) 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08806455T PL2205603T3 (pl) 2007-09-28 2008-09-29 Pochodne pirymidyny jako inhibitory kinaz białkowych

Country Status (9)

Country Link
US (3) US8563542B2 (enExample)
EP (2) EP2205603B1 (enExample)
JP (2) JP5410432B2 (enExample)
CN (1) CN101878216B (enExample)
CA (1) CA2700979C (enExample)
ES (2) ES2457394T3 (enExample)
PL (2) PL2610256T3 (enExample)
RU (2) RU2478100C2 (enExample)
WO (1) WO2009040556A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
NZ583061A (en) 2007-08-15 2012-06-29 Vertex Pharma 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
NZ584760A (en) 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
WO2009040556A1 (en) 2007-09-28 2009-04-02 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
JP5634990B2 (ja) 2008-06-23 2014-12-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質キナーゼ阻害剤
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
CN104151312B (zh) 2009-06-17 2016-06-15 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
RU2012116525A (ru) * 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения перемидиновых производных, пригодных в качестве ингибиторов протеинкиназ
JP2013512860A (ja) 2009-09-25 2013-04-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法
CA2797947C (en) 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
HRP20172006T1 (hr) 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
HUE044667T2 (hu) 2013-11-13 2019-11-28 Vertex Pharma Influenza vírus replikáció inhibitorok
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
KR101517414B1 (ko) * 2014-04-24 2015-05-04 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
PT3233882T (pt) 2014-12-16 2020-01-21 Kayla Therapeutics Dinucleótidos cíclicos fluorados para a indução de citocinas
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
KR20180114057A (ko) * 2016-03-04 2018-10-17 안후이 뉴 스타 파마슈티컬 디벨롭먼트 컴퍼니 리미티드 피리미딘 7-원 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물, 및 이의 용도
US11155556B2 (en) * 2016-04-07 2021-10-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders
BR112020008833A2 (pt) * 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
CN112166113A (zh) 2017-11-02 2021-01-01 卡里科生命科学有限责任公司 整合应激通路的调节剂
US20220289755A1 (en) 2019-08-16 2022-09-15 Cyclacel Limited Process for the preparation of a pyrimidino-diazepine derivative
CN114269752A (zh) * 2019-08-16 2022-04-01 西克拉塞尔有限公司 嘧啶并二氮杂环庚三烯衍生物的结晶形式
EP4034132A4 (en) * 2019-09-27 2023-10-11 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
CN119365489A (zh) 2022-04-08 2025-01-24 印希比生物科学有限公司 Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117635D0 (en) 1991-08-15 1991-10-02 British Telecomm Phase shifter
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
BR0318145A (pt) * 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
WO2005117944A2 (en) 2004-05-26 2005-12-15 The Texas A & M University System Hsp20 inhibits amyloidogenesis and neurotoxicity
AU2005294575B2 (en) * 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
CN101203491A (zh) 2005-06-24 2008-06-18 伊莱利利公司 可用作雄激素受体调节剂的四氢咔唑衍生物（sarm）
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008113711A1 (en) * 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
WO2009040556A1 (en) 2007-09-28 2009-04-02 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment

Also Published As

Publication number Publication date
JP2010540509A (ja) 2010-12-24
US20150344486A1 (en) 2015-12-03
US20140066436A1 (en) 2014-03-06
EP2610256A1 (en) 2013-07-03
EP2205603A1 (en) 2010-07-14
PL2205603T3 (pl) 2014-07-31
CN101878216B (zh) 2013-07-10
EP2205603B1 (en) 2014-01-15
ES2457394T3 (es) 2014-04-25
RU2010116759A (ru) 2011-11-10
HK1187895A1 (en) 2014-04-17
EP2610256B1 (en) 2016-04-27
RU2013108456A (ru) 2014-09-10
US9133199B2 (en) 2015-09-15
US8563542B2 (en) 2013-10-22
RU2478100C2 (ru) 2013-03-27
US20110046093A1 (en) 2011-02-24
CA2700979C (en) 2017-06-20
JP2014076994A (ja) 2014-05-01
CN101878216A (zh) 2010-11-03
CA2700979A1 (en) 2009-04-02
WO2009040556A1 (en) 2009-04-02
HK1146042A1 (en) 2011-05-13
JP5863196B2 (ja) 2016-02-16
ES2585110T3 (es) 2016-10-03
JP5410432B2 (ja) 2014-02-05
RU2623221C2 (ru) 2017-06-23
US9493471B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
HUS1900014I1 (hu) Proteinkináz inhibitorok
IL210124A0 (en) Pyrimidine derivatives as kinase inhibitors
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
ZA201004243B (en) Benzofuropyrimidinones as protein kinase inhibitors
IL218543A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
SI2193133T1 (sl) Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
IL202835A0 (en) Pyrimidine derivatives useful as raf kinase inhibitors
IL196554A0 (en) Heteroaryl derivatives as protein kinase inhibitors
HRP20130796T1 (en) Pyrimidine derivatives used as pi-3 kinase inhibitors
PL2203449T3 (pl) Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
PT2197880E (pt) Compostos heterocíclicos bicíclicos como inibidores da proteína tirosina cinase
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL210073A0 (en) Protein kinase inhibitors
IL210069A0 (en) Protein kinase inhibitors
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
HK1150829A (en) Pyrimidine derivatives as kinase inhibitors
GB0715470D0 (en) IKK- serine-threonine protein kinase inhibitors
HK1134814A (en) Benzofuropyrimidinones as protein kinase inhibitors
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors